Document Detail

Clinical relevance of urethral stents (urospiral 2™) placement in patients with prostatic obstacle and concomitant high-risk surgical status or neurological diseases: A feasibility and safety study.
MedLine Citation:
PMID:  20860015     Owner:  NLM     Status:  In-Data-Review    
AIMS: To review the indications and to assess the functional outcomes after placement of a new temporary urethral stent (TUS) in men with lower urinary tract dysfunction.
METHODS: We retrospectively reviewed the data of men with prostate obstruction and concomitant high-risk surgical status or neurological diseases between 2006 and 2008. TUS placement was performed with Urospiral 2™ which is a temporary, non-expanding, transprostatic stent. Success was defined as follows: when TUS placement allowed patients to void spontaneously and/or when surgery was made feasible after the period of relative contraindication (therapeutic group) or when TUS placement allowed physicians to define the role of prostate obstruction in the patients' voiding disorders and therefore to make an appropriate therapeutic decision (diagnosis group).
RESULTS: We included 94 men with a mean age of 73.3 ± 9 years (48-99) and 5 of them were lost to follow-up. The mean follow-up was 148 ± 100 days (2-1,046) and the mean duration of TUS placement was 155 ± 90 days (2-1,045). After a mean hospital stay of 4.8 ± 3 days (1-31), 84 patients (89%) had recovered spontaneous micturition. In the therapeutic group and the diagnosis group, 23 patients (92%) and 45 patients (70%) voided spontaneously, respectively.
CONCLUSIONS: TUS placement may be proposed temporarily in selected patients with static bladder outlet obstruction due to an enlarged prostate as it allows patients to avoid the use of an indwelling catheter. Neurourol. Urodynam. 30:374-379, 2011. © 2010 Wiley-Liss, Inc.
Morgan Rouprêt; Vincent Misraï; Aude de Fourmestraux; Florence Cour; François Richard; Emmanuel Chartier-Kastler
Related Documents :
11329825 - Benign prostatic hyperplasia and erectile dysfunction--is there a link?
11895205 - I-125 versus pd-103 for low-risk prostate cancer: morbidity outcomes from a prospective...
9285305 - Pharmacotherapy of benign prostatic hyperplasia: inhibitor of 5 alpha-reductase.
11396235 - Oral estramustine therapy in serum chromogranin a-positive stage d3 prostate cancer pat...
12227905 - Transutricular seminal vesiculoscopy.
19300325 - Effect of transobturator tape on overactive bladder symptoms and urge urinary incontine...
Publication Detail:
Type:  Journal Article     Date:  2010-09-21
Journal Detail:
Title:  Neurourology and urodynamics     Volume:  30     ISSN:  1520-6777     ISO Abbreviation:  Neurourol. Urodyn.     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-03-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8303326     Medline TA:  Neurourol Urodyn     Country:  United States    
Other Details:
Languages:  eng     Pagination:  374-9     Citation Subset:  IM    
Copyright Information:
Copyright © 2010 Wiley-Liss, Inc.
ACADEMIC Department of Urology, Groupe Hospitalo-Universitaire EST, Pitié-Salpétrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Faculté de Médecine Pierre et Marie Curie, University Paris VI, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Exploring the mechanisms of intravesical electrical stimulation in the in vitro rat whole bladder af...
Next Document:  Intravesical immune suppression by liposomal tacrolimus in cyclophosphamide-induced inflammatory cys...